Alzheimer disease （AD） is a chronic neurodegenerative disorder with insidious onset and gradual aggravation， with complex pathogenesis. At present， there is no drug to reverse the course of the disease. CRISPR/Cas9 technology has the advantages of short cycle， low cytotoxicity， low price and simple transmission. Because it can be genetically modified for different cells， tissues or animal models， it shows great potential in the study of neurodegenerative diseases. This paper introduces the development， principle and delivery system of CRISPR/Cas9 technology， as well as the application and potential of CRISPR/Cas9 technology in AD model construction， pathogenesis research and targeted therapy， hoping to play a reference role for researchers in related fields.